The value of cysteinyldopa in the follow-up of disseminated malignant melanoma
Authors:
- B. KågedalBKB. Kågedal
- C. LindholmCLC. Lindholm
- B. NilssonBNB. Nilsson
- K. ÅrstrandKÅK. Årstrand
- U. RingborgURU. Ringborg
- 1 August 2000
- journal article
- research article
- Published by Wolters Kluwer Health in Melanoma Research
- Vol. 10 (4) , 363-369
Abstract
In a series of 92 patients with malignant melanoma, clinical stage III or IV, both 5-S-cysteinyldopa (5SCD) and 6-hydroxy-5-methoxyindole-2-carboxylic acid (6H5MI2C) were measured in urine during chemotherapy. A total of 434 urine specimens were analysed. The sensitivity of 5SCD for the detection of stage III–IV melanoma was 83%, while the corresponding sensitivity of 6H5MI2C was 52%. Fifty per cent of patients with one metastatic site had increased 5SCD excretion, while all patients with four or more metastatic sites had increased excretion. A significant correlation was found between 5SCD decrease and clinical regression ( P < 0.001) and between 5SCD increase and clinical progression ( P < 0.001). Corresponding correlations were not found for 6H5MI2C. Increments in 5SCD excretion (median 269 μmol/mol creatinine) were seen for 83% of the occasions when clinical progression was recorded, and decrements in 5SCD excretion (median 145 μmol/mol creatinine) were seen for 85% of the occasions when clinical regression was seen. During clinical ‘stable disease’ increases in 5SCD excretion were seen in 59% and decreases in 41%. The median value of 5SCD changes for stable disease was 7.0 μmol/mol creatinine, indicating a chemical marker stability in many cases. We recommend the use of 5SCD in urine as a valuable, reliable and simple biochemical marker to use in the clinical follow-up of melanoma patients with advanced disease.Keywords
This publication has 14 references indexed in Scilit:
- Determination of 5-S-cysteinyldopa in plasma and urine using a fully automated solid-phase extraction–high-performance liquid chromatographic method for an improvement of specificity and sensitivity of this prognostic marker of malignant melanomaJournal of Chromatography B: Biomedical Sciences and Applications, 1999
- S100B protein, 5-S-cysteinyldopa and 6-hydroxy-5- methoxyindole-2-carboxylic acid as biochemical markers for survival prognosis in patients with malignant melanomaMelanoma Research, 1997
- Serum levels of slCAM-1 and 5-S-cysteinyldopa as markers of melanoma progressionMelanoma Research, 1997
- High Plasma Level of a Eumelanin Precursor, 6-Hydroxy-5-Methoxyindole-2-Carboxylic Acid as a Prognostic Marker for Malignant MelanomaJournal of Investigative Dermatology, 1994
- Melanin Pigments and Melanosomal Proteins as Differentiation Markers Unique to Normal and Neoplastic MelanocytesJournal of Investigative Dermatology, 1993
- Serum 5‐S‐Cysteinyldopa (5‐S‐CD) as a Marker of Melanoma ProgressionThe Journal of Dermatology, 1992
- Melanin-related Metabolites as Markers of Melanoma: A ReviewThe Journal of Dermatology, 1992
- Automated high-performance liquid chromatographic determination of 5-S-cysteinyl-3,4-dihydroxyphenylalanine in urineJournal of Chromatography A, 1989
- Plasma 5-S-cysteinyldopa differentiates patients with primary and metastatic melanoma from patients with dysplastic nevus syndrome and normal subjectsJournal of the American Academy of Dermatology, 1988
- Analysis of eumelanin-related indolic compounds in urine by high-performance liquid chromatography with fluorimetric detectionJournal of Chromatography B: Biomedical Sciences and Applications, 1986